KAREN RABIN to Disease-Free Survival
This is a "connection" page, showing publications KAREN RABIN has written about Disease-Free Survival.
Connection Strength
0.911
-
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024 Jan 10; 42(2):218-227.
Score: 0.183
-
Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9).
Score: 0.116
-
Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Sep; 59(3):468-74.
Score: 0.080
-
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009 Mar; 144(6):930-2.
Score: 0.066
-
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
Score: 0.050
-
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 04; 38(4):720-728.
Score: 0.047
-
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
Score: 0.046
-
Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. Blood. 2023 04 13; 141(15):1802-1811.
Score: 0.044
-
Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022 05 01; 128(9):1863-1870.
Score: 0.041
-
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. Leukemia. 2022 03; 36(3):648-655.
Score: 0.040
-
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929.
Score: 0.038
-
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 10 01; 38(28):3282-3293.
Score: 0.037
-
Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer. 2020 02 01; 126(3):593-601.
Score: 0.035
-
Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Adv. 2019 06 11; 3(11):1647-1656.
Score: 0.034
-
Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018 10 10; 36(29):2926-2934.
Score: 0.032
-
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7.
Score: 0.023